Similarly, therapeutics targeting mMSDCs (fludarabine) versus gMDSCs (anti-IL1β) had sex-dependent effects on GBM tumor growth in murine models, with fludarabine treatment decreasing tumor growth solely in males and anti-IL1β treatment decreasing tumor growth solely in females (38). The gene discussed is IL1B; the disease is glioblastoma.